Company intelligence / Profile preview
Hyundai Bioscience
Gangseo-gu, Seoul, South Koreahyundaibioscience.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Hyundai Bioscience is a clinical-stage South Korean biotech company focused on repurposing existing drugs using proprietary drug delivery systems. Its lead programs target infectious diseases such as COVID‑19 with broad-spectrum antivirals, and cancer with less toxic therapies. The company has initiated at least one Phase 1 trial for its antiviral candidate CP-COV03 and has developed several cosmetic/consumer health products based on its DDS platform. It also maintains manufacturing capabilities in Korea.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Small moleculePolymer-drug conjugate therapyDrug delivery system
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
CMG PharmaceuticalYOOYOUNG Pharmaceutical
Beyond the preview
Go deeper on Hyundai Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyundai Bioscience.